| Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 (NCT00866138) | AB Science | 2005-02-01 |
| UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients (NCT00111748) | University of Arkansas | 2005-02-01 |
| A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma (NCT00229203) | PharmaMar | 2005-02-01 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients (NCT00103662) | Genzyme, a Sanofi Company | 2005-01-01 |
| Behavioral Intervention For BMT/SCT Survivors (NCT00579917) | Memorial Sloan Kettering Cancer Center | 2005-01-01 |
| Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma (NCT00396045) | University of Turin, Italy | 2005-01-01 |
| A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma (NCT00097981) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-01-01 |
| Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma (NCT00131261) | Valerio Therapeutics | 2005-01-01 |
| AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF (NCT00396266) | Genzyme, a Sanofi Company | 2005-01-01 |
| Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies (NCT00113828) | Massachusetts General Hospital | 2004-12-01 |
| Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma (NCT00151203) | Weill Medical College of Cornell University | 2004-12-01 |
| Stage I Multiple Myeloma Treatment (NCT00733538) | Centre Hospitalier Universitaire de Nice | 2004-12-01 |
| VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma (NCT00111319) | Millennium Pharmaceuticals, Inc. | 2004-12-01 |
| Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma (NCT00427765) | M.D. Anderson Cancer Center | 2004-12-01 |
| Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma (NCT00103506) | Janssen Research & Development, LLC | 2004-12-01 |
| Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients (NCT00358020) | University of Turin, Italy | 2004-11-01 |
| VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands (NCT00440765) | Janssen-Cilag B.V. | 2004-11-01 |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma (NCT00064038) | SWOG Cancer Research Network | 2004-11-01 |
| Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation (NCT00396383) | Genzyme, a Sanofi Company | 2004-11-01 |
| Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma (NCT00099047) | National Cancer Institute (NCI) | 2004-11-01 |
| Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (NCT00095680) | Scios, Inc. | 2004-11-01 |
| Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma (NCT00113841) | M.D. Anderson Cancer Center | 2004-11-01 |
| Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (NCT00985907) | University of California, San Francisco | 2004-10-28 |
| A Multiple Myeloma Trial in Patients With Bone Metastases (NCT00104104) | Novartis Pharmaceuticals | 2004-10-01 |
| A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma (NCT00516191) | University of California, San Francisco | 2004-10-01 |
| Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients (NCT00322842) | Genzyme, a Sanofi Company | 2004-09-01 |
| Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma (NCT00287872) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2004-09-01 |
| Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies (NCT00513318) | University of California, San Francisco | 2004-08-01 |
| Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma (NCT00153933) | Dana-Farber Cancer Institute | 2004-08-01 |
| Bortezomib With Melphalan and Prednisone for Multiple Myeloma (NCT00734149) | Duke University | 2004-07-01 |
| Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. (NCT00299780) | Massachusetts General Hospital | 2004-07-01 |
| Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma (NCT00201695) | Ohio State University Comprehensive Cancer Center | 2004-07-01 |
| Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma (NCT00135187) | University of Michigan Rogel Cancer Center | 2004-07-01 |
| The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma (NCT00459069) | Beth Israel Deaconess Medical Center | 2004-07-01 |
| Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (NCT00087867) | Scios, Inc. | 2004-06-01 |
| Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation (NCT00185757) | Stanford University | 2004-06-01 |
| UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients (NCT00113919) | University of Arkansas | 2004-06-01 |
| Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma (NCT00090493) | University of Arkansas | 2004-06-01 |
| A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients (NCT00752518) | Janssen Pharmaceutical K.K. | 2004-05-01 |
| Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma (NCT00086216) | Callisto Pharmaceuticals | 2004-05-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma (NCT00193557) | SCRI Development Innovations, LLC | 2004-05-01 |
| Autologous Transplant for Multiple Myeloma (NCT00177047) | Masonic Cancer Center, University of Minnesota | 2004-04-20 |
| Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. (NCT00388635) | PETHEMA Foundation | 2004-04-01 |
| Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence (NCT00123773) | AHS Cancer Control Alberta | 2004-04-01 |
| Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients (NCT00322387) | Genzyme, a Sanofi Company | 2004-04-01 |
| Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. (NCT00242528) | Novartis | 2004-04-01 |
| Family Study of Lymphoproliferative Disorders (NCT00626496) | Mayo Clinic | 2004-04-01 |
| Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma (NCT00079716) | Seagen Inc. | 2004-03-01 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients (NCT00322491) | Genzyme, a Sanofi Company | 2004-03-01 |
| Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma (NCT00080405) | Millennium Pharmaceuticals, Inc. | 2004-03-01 |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients (NCT00661544) | M.D. Anderson Cancer Center | 2004-03-01 |
| Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma (NCT00083564) | Poniard Pharmaceuticals | 2004-03-01 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor (NCT00304720) | Colorado Blood Cancer Institute | 2004-03-01 |
| Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma (NCT00581919) | University of Wisconsin, Madison | 2004-02-01 |
| Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (NCT00093028) | University of Arkansas | 2004-01-01 |
| CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (NCT00091260) | Vaishali Sanchorawala | 2004-01-01 |
| UARK 2003-33, Total Therapy III (NCT00081939) | University of Arkansas | 2004-01-01 |
| Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma (NCT00440635) | Janssen-Cilag International NV | 2004-01-01 |
| Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma (NCT00504634) | M.D. Anderson Cancer Center | 2004-01-01 |
| Post Transplant Donor Lymphocyte Infusion (NCT00167180) | Masonic Cancer Center, University of Minnesota | 2004-01-01 |
| S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis (NCT00064337) | SWOG Cancer Research Network | 2004-01-01 |
| Protein Tyrosine Kinases (PTK) in Multiple Myeloma (NCT00165347) | Dana-Farber Cancer Institute | 2003-12-01 |
| UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma (NCT00113932) | University of Arkansas | 2003-12-01 |
| CP-751,871 Treatment For Patients With Multiple Myeloma (NCT01536145) | Pfizer | 2003-12-01 |
| Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer (NCT00255684) | University of Rochester | 2003-12-01 |
| Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) (NCT00075829) | National Heart, Lung, and Blood Institute (NHLBI) | 2003-12-01 |
| A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) (NCT00109109) | Merck Sharp & Dohme LLC | 2003-12-01 |
| Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. (NCT00145652) | Sundsvall Hospital | 2003-12-01 |
| Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma (NCT00067639) | M.D. Anderson Cancer Center | 2003-12-01 |
| Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma (NCT00153920) | Dana-Farber Cancer Institute | 2003-12-01 |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. (NCT00919139) | SWOG Cancer Research Network | 2003-11-01 |
| Xcellerated T CellsTM in Patients With Multiple Myeloma (NCT00078065) | Xcyte Therapies | 2003-11-01 |
| Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma (NCT01296503) | Grupo de Estudos Multicentricos em Onco-Hematologia | 2003-10-01 |
| Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant (NCT00089453) | University of Arkansas | 2003-09-01 |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma (NCT00400686) | The Cleveland Clinic | 2003-09-01 |
| Therapeutic Research in Multiple Myeloma (NCT00572338) | University of Arkansas | 2003-08-01 |
| Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NCT00337506) | Nantes University Hospital | 2003-08-01 |
| Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma (NCT00118339) | Fred Hutchinson Cancer Center | 2003-07-01 |
| Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma (NCT00065351) | Celgene | 2003-07-01 |
| Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) (NCT00633542) | Università Politecnica delle Marche | 2003-06-01 |
| Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure (NCT00062621) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-06-01 |
| Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) (NCT00215943) | H. Lee Moffitt Cancer Center and Research Institute | 2003-06-01 |
| The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma (NCT00207805) | Centre National de Greffe de Moelle Osseuse | 2003-05-01 |
| Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (NCT00060645) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Phase I Study of Sequential Cord Blood Transplants (NCT00299767) | Massachusetts General Hospital | 2003-05-01 |
| An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma (NCT02182141) | Boehringer Ingelheim | 2003-04-01 |
| Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (NCT00060632) | Merck Sharp & Dohme LLC | 2003-04-01 |
| Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (NCT00143845) | University of Michigan Rogel Cancer Center | 2003-04-01 |
| A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma (NCT00622336) | Celgene | 2003-04-01 |
| Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells (NCT00186316) | Stanford University | 2003-04-01 |
| A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) (NCT00091624) | Celgene Corporation | 2003-03-01 |
| A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies (NCT00621244) | Novartis Pharmaceuticals | 2003-03-01 |
| A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma (NCT00057564) | Celgene Corporation | 2003-02-01 |
| FREE Study - Fracture Reduction Evaluation (NCT00211211) | Medtronic Spine LLC | 2003-02-01 |
| CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma (NCT00056160) | Celgene | 2003-01-01 |
| A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma (NCT00424047) | Celgene | 2003-01-01 |
| Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF (NCT00952237) | Dartmouth-Hitchcock Medical Center | 2003-01-01 |
| Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma (NCT00327314) | Azienda Ospedaliera San Giovanni Battista | 2002-12-01 |
| Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer (NCT00053196) | Alliance for Clinical Trials in Oncology | 2002-12-01 |